Načítá se...
Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease
Hydroxyurea is an excellent therapeutic agent for the pharmacological induction of HbF in patients with sickle cell disease (SCD). However, all completed clinical trials of hydroxyurea have excluded patients with hemoglobin SC (HbSC) disease. HbSC differs significantly in pathophysiology from HbSS,...
Uloženo v:
| Vydáno v: | Exp Biol Med (Maywood) |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4950384/ https://ncbi.nlm.nih.gov/pubmed/26993671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1535370216639737 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|